MedTrace Logo

A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs).

NCT04319367 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2024-04-17

No results posted yet for this study

Summary

RIO is a placebo-controlled double-blinded two arm prospective phase II randomised controlled trial . This study will test the use of broadly neutralising antibodies (bNAbs) in participants with treated primary HIV infection (PHI).

Conditions

  • HIV/AIDS and Infections

Interventions

DRUG

Investigational Medicinal Product

Recombinant human monoclonal antibody (mAb) or placebo

Sponsors & Collaborators

  • Bill and Melinda Gates Foundation

    collaborator OTHER

  • University of Oxford

    collaborator OTHER

  • Rockefeller University

    collaborator OTHER

  • Imperial College London

    lead OTHER

Principal Investigators

  • Sarah Fidler, MBBS, Ph.D · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-17
Primary Completion
2027-07-31
Completion
2027-07-31

Countries

  • Denmark
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04319367 on ClinicalTrials.gov